Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism

被引:104
|
作者
Ding, WG
Renstrom, E
Rorsman, P
Buschard, K
Gromada, J
机构
[1] NOVO NORDISK AS,DEPT ISLET CELL PHYSIOL,DK-2100 COPENHAGEN,DENMARK
[2] KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,COPENHAGEN,DENMARK
关键词
D O I
10.2337/diabetes.46.5.792
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
High-resolution capacitance measurements were used to explore the effects of the gut hormones GLP-I(7-36) amide [glucagon-Like peptide I(7-36) amide] and GIP (glucose-dependent insulinotropic polypeptide) on Ca2+-dependent exocytosis in glucagon-secreting rat pancreatic alpha-cells, Both peptides produced a greater than threefold potentiation of secretion evoked by voltage-clamp depolarizations, an effect that was associated with an similar to 35% increase of the Ca2+ current. The stimulatory actions of GLP-I(7-36) amide and GIP were mimicked by forskolin and antagonized by the protein kinase A (PKA)inhibitor Rp-8-Br-cAMPS. The islet hormone somatostatin inhibited the stimulatory action of GLP-I(7-36) amide and GIP via a cyclic AMP-independent mechanism, whereas insulin had no effect on exocytosis. These data suggest that the alpha-cells are equipped with receptors for GLP-I and GIP and that these peptides, in addition to their well-established insulinotropic capacity, also stimulate glucagon secretion. We propose that the reported inhibitory action of GLP-I on glucagon secretion is accounted for by a paracrine mechanism (e.g., mediated by stimulated release of somatostatin that in turn suppresses exocytosis in the alpha-cell).
引用
收藏
页码:792 / 800
页数:9
相关论文
共 50 条
  • [41] Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
    Goldenberg, Ronald M.
    Teoh, Hwee
    Verma, Subodh
    CURRENT OPINION IN CARDIOLOGY, 2023, 38 (06) : 539 - 545
  • [42] Expression of glucagon-like peptide-1 receptor and glucose-dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells
    Aoyama, Emina
    Watari, Ippei
    Podyma-Inoue, Katarzyna Anna
    Yanagishita, Masaki
    Ono, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 (02) : 475 - 482
  • [43] Expression of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in the rat submandibular gland is influenced by pre- and post-natal high-fat diet exposure
    Sangsuriyothai, Pornchanok
    Watari, Ippei
    Serirukchutarungsee, Saranya
    Satrawaha, Sirichom
    Podyma-Inoue, Katarzyna Anna
    Ono, Takashi
    FRONTIERS IN PHYSIOLOGY, 2024, 15
  • [44] INVESTIGATIONS INTO THE ACTIONS OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AND GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE ON LIPOPROTEIN-LIPASE ACTIVITY IN EXPLANTS OF RAT ADIPOSE-TISSUE
    KNAPPER, JME
    PUDDICOMBE, SM
    MORGAN, LM
    FLETCHER, JM
    JOURNAL OF NUTRITION, 1995, 125 (02): : 183 - 188
  • [45] Glucose-dependent insulinotropic polypeptide (GIP) does not potentiate the antidiabetic effects of glucagon-like peptide-1 (GLP-1) in hyperglycaemic patients with type 2 diabates mellitus
    Mentis, N.
    Nauck, M. A.
    Kothe, L.
    Holst, J. J.
    Deacon, C.
    Theodorakis, M.
    Vardarli, I.
    DIABETOLOGIA, 2009, 52 : S312 - S312
  • [46] Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice
    Iwamoto, Yuichiro
    Kimura, Tomohiko
    Dan, Kazunori
    Iwamoto, Hideyuki
    Sanada, Junpei
    Fushimi, Yoshiro
    Katakura, Yukino
    Shimoda, Masashi
    Yamasaki, Yuki
    Nogami, Yuka
    Shirakiya, Yoshiko
    Nakanishi, Shuhei
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    DIABETES OBESITY & METABOLISM, 2024,
  • [47] Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice
    Ahrén, B
    Hughes, TE
    ENDOCRINOLOGY, 2005, 146 (04) : 2055 - 2059
  • [48] Tirzepatide: A Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus (vol 30, pg e26, 2023)
    Wong, E.
    Cope, R.
    Dima, L.
    Nguyen, T.
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (03) : E311 - E311
  • [49] The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
    Wilson, Jonathan M.
    Lin, Yanzhu
    Luo, M. Jane
    Considine, Gary
    Cox, Amy L.
    Bowsman, Lenden M.
    Robins, Deborah A.
    Haupt, Axel
    Duffin, Kevin L.
    Ruotolo, Giacomo
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 148 - 153
  • [50] Heterologous desensitization of insulin secretion by GIP (glucose-dependent insulinotropic peptide) in INS-1 cells:: the significance of Gαi2 and investigations on the mechanism involved
    Rucha, A
    Verspohl, EJ
    CELL BIOCHEMISTRY AND FUNCTION, 2005, 23 (03) : 205 - 212